Capromorelin Tartrate

SKU: orb1296264

Description

Capromorelin Tartrate

Research Area

Product Categories/Products/Small Molecules,GPCR/G Protein

Key Properties

• CAS Number: 193273-69-7
• MW: 655.7
• Purity: 97.69%
• Formula: C₃₂H₄₁N₅O₁₀
• SMILES: O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N

Bioactivity

• Target IC50:
  GHS-R1a (human):7 nM (Ki)
• In Vivo:
  Capromorelin demonstrates enhanced intestinal absorption in rodent models and exhibits superior pharmacokinetic properties, including high bioavailabilities in rats (F=65%) and dogs (F=44%) . It stimulates GH release in anesthetized rats with an ED50 of 0.05 mg/kg iv . In dogs, capromorelin (30 mg/mL) significantly increases food consumption and results in a weight gain of 0.52 kg compared to the placebo group .
• In Vitro:
  Capromorelin stimulates GH release in rat pituitary cell cultures (EC50: 3 nM) .
• Animal Research:
  The study tested capromorelin flavored oral solution with 30 mg/mL of capromorelin compared to a matched placebo flavored oral solution treatment (which contains all the ingredients of the formulation without capromorelin) administered for 4 days. Dogs are randomized into two groups, with Group 1 receiving placebo (0.1 mL/kg) and Group 2 receiving 3.0 mg/kg. Both groups are treated once a day at approximately 9 AM each day. The first day of dosing is considered Day 0. The placebo and test drug are administered by a syringe placed in the corner of the mouth. The Day 0 weight is used for dose calculations .

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

9852610